The Brazil Leukemia Therapeutics size stood at USD xx million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Leukemia therapeutics is a haematological cancer of blood-forming tissues, including the blood components and bone marrow. It is occurred when bone marrow produces damaged lymphocytes which causes dysfunctional in production of antibodies and ultimately lost the ability to fight against infections. The various factors such as genetic mutation and family history of leukaemia are major causes of leukaemia.
The leukemia therapeutics market is expected to witness high growth due to rising incidences of chronic diseases. Leukemia is identified by the spread of disease (acute and chronic) commonly caused due to exposure to radiation, unhealthy lifestyle habits, and environmental factors. Increasing geriatric population base and high unmet needs regarding early diagnosis and treatment of leukemia are the key factors driving the market.
Additionally, increasing investments in the R&D sector, introduction of novel therapies with more efficiency & fewer side effects.
Major types of Leukaemia
The leukemia therapeutics market includes types of diseases such as chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia, and acute myeloid leukemia. The chronic myeloid leukemia market dominated the overall therapeutic market owing to high prevalence rate, high drug treatment rates and rapid uptake of second-generation tyrosine kinase inhibitors.